Visionblue is a drug owned by Dorc International Bv. It is protected by 2 US drug patents filed in 2018 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 26, 2019. Details of Visionblue's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6367480 | Methods for visualizing the anterior lens capsule of the human eye |
Oct, 2019
(5 years ago) |
Expired
|
| US6720314 | Use of a vital dye for facilitating surgical procedures for cataract extraction |
May, 2019
(5 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Visionblue is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Visionblue's family patents as well as insights into ongoing legal events on those patents.
Visionblue's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Visionblue's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 26, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Visionblue Generics:
There are no approved generic versions for Visionblue as of now.
Alternative Brands for Visionblue
Visionblue which is used for facilitating removal of lens substance during cataract surgery., has several other brand drugs using the same active ingredient (Trypan Blue). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Dorc |
|
About Visionblue
Visionblue is a drug owned by Dorc International Bv. It is used for facilitating removal of lens substance during cataract surgery. Visionblue uses Trypan Blue as an active ingredient. Visionblue was launched by Dorc in 2004.
Approval Date:
Visionblue was approved by FDA for market use on 16 December, 2004.
Active Ingredient:
Visionblue uses Trypan Blue as the active ingredient. Check out other Drugs and Companies using Trypan Blue ingredient
Treatment:
Visionblue is used for facilitating removal of lens substance during cataract surgery.
Dosage:
Visionblue is available in solution form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.06% | SOLUTION | Prescription | OPHTHALMIC |